Biomea Fusion, Inc. financial data

Symbol
BMEA on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Middlefield Road, 4 Th Floor, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 532 % -42.7%
Debt-to-equity 26.9 % +65.7%
Return On Equity -119 % -69.9%
Return On Assets -93.7 % -55.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +1.49%
Common Stock, Shares, Outstanding 36.2M shares +1.51%
Entity Public Float 597M USD +133%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +1.59%
Weighted Average Number of Shares Outstanding, Diluted 36.2M shares +1.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.07B USD 0%
Research and Development Expense 124M USD +34.1%
General and Administrative Expense 27.6M USD +20.8%
Operating Income (Loss) -151M USD -31.5%
Net Income (Loss) Attributable to Parent -144M USD -33.7%
Earnings Per Share, Basic -4.01 USD/shares -20.1%
Earnings Per Share, Diluted -4.01 USD/shares -20.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 88M USD -55.8%
Assets, Current 93.6M USD -53.8%
Property, Plant and Equipment, Net 4.23M USD -24.2%
Operating Lease, Right-of-Use Asset 7.6M USD -35.7%
Other Assets, Noncurrent 4.63M USD -4.14%
Assets 110M USD -50.9%
Accounts Payable, Current 8.99M USD +181%
Employee-related Liabilities, Current 5.64M USD +18.8%
Liabilities, Current 27.6M USD +70.1%
Operating Lease, Liability, Noncurrent 6.88M USD -25.8%
Liabilities 34.4M USD +35.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +90%
Retained Earnings (Accumulated Deficit) -358M USD -67.3%
Stockholders' Equity Attributable to Parent 76M USD -61.9%
Liabilities and Equity 110M USD -50.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32M USD -33.2%
Net Cash Provided by (Used in) Financing Activities 116K USD -42.3%
Net Cash Provided by (Used in) Investing Activities -35K USD +98%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 36.2M shares +1.51%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.9M USD -24.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 88.3M USD -55.7%
Deferred Tax Assets, Valuation Allowance 71.5M USD +161%
Deferred Tax Assets, Gross 74.6M USD +167%
Operating Lease, Liability 11.1M USD -16.9%
Depreciation 1.64M USD +34.8%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -144M USD -33.7%
Lessee, Operating Lease, Liability, to be Paid 15.3M USD -18.8%
Property, Plant and Equipment, Gross 7.94M USD +4.64%
Operating Lease, Liability, Current 2.69M USD -4.71%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.53M USD -44.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.9M USD -28.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.23M USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.44M USD +4.57%
Deferred Tax Assets, Operating Loss Carryforwards 31.5M USD +160%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.22M USD +255%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +3.01%
Operating Lease, Payments 2.27M USD +66%
Additional Paid in Capital 434M USD +4.93%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.04M USD +469%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%